Research programme: cyclin-dependent kinase inhibitors - Johnson & Johnson

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Johnson & Johnson

Alternative Names: JNJ 7706621; triazine-pyridine biheteroaryl series - Johnson & Johnson

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Class Antineoplastics
  • Mechanism of Action CDC2 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Sep 2007 Information from the 234th American Chemical Society National Meeting (234th-ACS-2007) added to the introduction
  • 19 Sep 2005 Data presented at the 230th American Chemical Society National Meeting - (230th-ACS-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top